Share Name Share Symbol Market Type Share ISIN Share Description
Emis Group Plc LSE:EMIS London Ordinary Share GB00B61D1Y04 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  28.00 2.67% 1,078.00 110,006 16:35:14
Bid Price Offer Price High Price Low Price Open Price
1,068.00 1,074.00 1,078.00 1,044.00 1,068.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Software & Computer Services 159.51 27.07 36.00 29.9 682
Last Trade Time Trade Type Trade Size Trade Price Currency
16:50:20 O 1,903 1,059.185 GBX

Emis (EMIS) Latest News (1)

More Emis News
Emis Takeover Rumours

Emis (EMIS) Discussions and Chat

Emis Forums and Chat

Date Time Title Posts
15/9/202013:55EMIS - Healthcare IT608

Add a New Thread

Emis (EMIS) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Emis trades in real-time

Emis (EMIS) Top Chat Posts

Emis Daily Update: Emis Group Plc is listed in the Software & Computer Services sector of the London Stock Exchange with ticker EMIS. The last closing price for Emis was 1,050p.
Emis Group Plc has a 4 week average price of 1,006p and a 12 week average price of 985p.
The 1 year high share price is 1,250p while the 1 year low share price is currently 722p.
There are currently 63,311,396 shares in issue and the average daily traded volume is 58,334 shares. The market capitalisation of Emis Group Plc is £682,496,848.88.
grahamburn: From Investors Chronicle daily round up: EMIS’ (EMIS) strategy to separate its good and bad news into two different announcements has not fooled investors. Shares in the healthcare software provider fell 17 per cent in early trading on the revelation that its Web product for GPs in England has failed to meet certain services levels and reporting obligations. The financial impact of this problem is expected to be “in the order of upper digits of millions of pounds”, according to management, who are working with NHS Digital to assess the full scale of the impact and attempt to resolve the matter. The group’s second update - an inline trading statement - made for much more pleasant reading, but after taking into account the one-off charge broker Numis has slashed its 2018 guidance. If the problems with Web products can be restricted to one off costs this morning’s share price fall presents an excellent buying opportunity, but we place our recommendation under review for now as we await more details on the extent of the damage.
garry1000: I hear that 10% of the work force is getting cut to boost the share price
waterloo01: Sorry been out of these awhile but the £10m figure taken from header bar here, however looking at last years full numbers (2015) the profit for the year was £5.3m (so 100 x) I'm probably working out incorrectly? htTp://
aishah: TechMarketView: EMIS battles headwinds in NHS IT market Healthcare software and services provider EMIS describes an “increasingly difficult environment” in the UK market in today’s trading update. Although EMIS’ overall performance for the year to the end of December was in line with the Board’s expectations, it’s clear that the severe pressures on NHS funds and a pause in procurement whilst the NHS’ Sustainability and Transformation Plans (STPs) were published have made it tough going. EMIS’ share price dipped some 6% on the news in early trading to c887p. We’ll need to wait for the full results in March to see the figures, but the headlines suggest that in Primary Care, EMIS’ heartland, it is maintaining market share and in Community, Children’s and Mental Health it is gaining market share. Secondary Care was most affected by the pressures on NHS funds but it performed largely in line with expectations thanks to the measures taken in the first half of 2016 (see here). In contrast, Specialist Care has been impacted by “operational inefficiencies”; and “additional costs associated with the implementation of its new contracts”, such that EMIS is considering a non-cash impairment charge to reflect the delay in contribution created by those additional costs. This is the division that offers image management and storage for the ophthalmology market, which requires rather a different business model to the software sales that EMIS is accustomed to. EMIS is focused on improving the profit profile of these new contracts but there’s clearly a risk that this move away from its software ‘knitting̵7; becomes an unwelcome and unprofitable distraction for the group. Whatever happens with Specialist Care, 2017 is set to be a busy, and we suspect challenging, year for EMIS. Q1 will see EMIS reorganise internally to bring primary, community and secondary care under common leadership, mirroring the NHS’ need to deliver more integrated care. And it’s continuing its search for a successor to CEO Chris Spencer who announced in December that he intends to retire by the end of the year (see here). ‘HeadwindsR17; will also remain a feature of the NHS IT market, but EMIS says it is confident of overcoming these and delivering a positive performance in 2017.
spong_1: Rampmeister, thanks for the info!Was wondering why the share price had been so flat the last few months.I think the trading update it's early March, so will definitely get back in before then...
ihatemms: Reddave- if you had waited around when they put staffline into their portfolio you would have paid an extra £2 per share (£10 to £12 within a week). You've got to get an initial holding in case the share price bolts off never to return as in the case of staff line.I bought a small amount of emis on t20 high initially but bought a lot more when it dropped back into the mid 10.50 .l then sold the initial purchase on the way back up again. That way I covered myself.
strollingmolby: I see EMIS will be presenting at the next AIM Investor Focus event, on 21 April. The companies selected to present at previous events have a strong track record of dividend increases and share price growth, so the selection of EMIS could be a lead indicator of more to come after the last twelve months: HTTP:// AIM Investor Focus has run since 2012. In total, 26 companies have participated at the event. Of the 26 companies that have presented, 20 have gone on to increase their dividend to shareholders at each subsequent opportunity.
xjhoward: Shares mag buy recommendation:EMIS plugged into digital healthNHS software supplier poised for overdue re-ratingAnalysts see potential for 35% share price upside at healthcare software supplier EMIS (EMIS:AIM) over the next six to 12 months. They expect the company to enjoy a strong re-rating as the market properly recognises the growth potential of its digital services supplied to the NHS.The £402 million cap Leeds-based company has won favourable terms as part of the GP Systems of Choice (GPSoC) framework agreement that will see it earn more on increased usage of the EMIS Web suite and digital patient records. This win was hinted at by chief executive officer Chris Spencer in December (see Griller, Shares, 19 Dec '13).But while the market anticipates EMIS Web will fuel immediate growth, new opportunities are also emerging. The company is building momentum in the UK community pharmacies space through its Rx suite, while opportunities are seen in community health, hospital pharmacy, accident and emergency (A&E) departments and mental health.
grahamg8: Mach100 being quiet may be good as it is easier to read considered comments without trawling through masses of garbage. My take on EMIS is that it has a pretty good track record. Growing revenue, operating profit, eps and dps. So this is a growth company and is currently on a P/E of 19.6, yield of 2.40% and cover of 2.125x on a share price of 666p. All well and good. To be more precise the growth in sales is 24%pa, eps 12%pa and dps 14%pa non compounded over three years. The big unknown is the investment of £57.5m in Ascribe -RNS 13/09/13. This could make or break EMIS as there is now a lot of debt on the books which is only going to be paid for if profitable sales result. If we trust the managers to continue to deliver then we invest; if the risks look too great then we sell up. Personally I'm on the fence, happy to hold at the current share price and see which way the story unfolds over the following months.
Emis share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200927 05:15:57